HER2-targeted therapies — a role beyond breast cancer | Nature Reviews Clinical Oncology
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars | SpringerLink
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance - ScienceDirect
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer
Evolution of anti-HER2 therapies for cancer treatment - ScienceDirect
Tucatinib, a HER2-Selective Tyrosine Kinase Inhibitor, Increases the Anti-tumor Activity of Trastuzumab Antibody-Drug Conjugate
Resistance and Overcoming Resistance in Breast Cancer | BCTT
ESMO E-Learning: Present and Emerging Treatment Options in HER2/NEU Overexpressing Metastatic Breast Cancer
Cancers | Free Full-Text | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer | HTML
Pipeline – Tucatinib (TUKYSA) – Seagen
Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma - Annals of Oncology
Cancers | Free Full-Text | The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer | HTML
Treatment Landscape for Patients with HER2-Positive Metastatic Breast | CMAR
Evolution of anti-HER2 therapies for cancer treatment - Cancer Treatment Reviews
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
Frontiers | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients | Oncology
Cancers | Free Full-Text | New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices? | HTML
Towards personalized treatment for early stage HER2-positive breast cancer | Nature Reviews Clinical Oncology
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
Tucatinib | C26H24N8O2 - PubChem
HER family in cancer progression: From discovery to 2020 and beyond - ScienceDirect
Emerging Treatments for HER2+ and Mutant Breast Cancer. Cristina Saura, MD, PhD Vall d Hebron University Hospital Barcelona, Spain - PDF Free Download
Novel targeted therapies for metastatic breast cancer. - Abstract - Europe PMC
cancers
HER2 TKIs for CNS Disease - HER2+ MBC - Module - HER2+ MBC Care - Oncology - Clinical Care Options
Cancers | Free Full-Text | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer | HTML
